TuHURA Biosciences draws $1.5 million more on Parkview credit facility

TuHURA Biosciences, Inc. disclosed in an 8-K dated November 2, 2026 that it had drawn an additional $1,500,000 under a revolving credit facility with Parkview Holdings One LLC. The company said it received and borrowed the funds on November 2, 2026, and plans to put the money toward general corporate purposes.¹

The borrowing comes under a loan agreement originally established earlier in the year. TuHURA Biosciences entered into the Loan Agreement with Parkview Holdings One LLC as lender on April 21, 2026.¹ That agreement set up a revolving credit line with a five-year term running to April 21, 2031, and a ceiling on total borrowing of $50 million.¹

The filing notes that the full terms of the arrangement are detailed in the original loan document, which TuHURA filed as an exhibit to its April 22, 2026 Current Report on Form 8-K.

Among the risks the company flagged in connection with this disclosure, TuHURA pointed to the possibility that it might not meet the conditions needed to draw further funds or stay in compliance with the loan terms, as well as the chance that the credit line might not provide enough capital to cover its operating and development needs going forward. The filing also noted a potential conflict of interest tied to the lender's relationship with TuHURA's largest stockholder, as described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed on March 31, 2026, and the Company's other reports and filings with the SEC.¹

The 8-K was signed by Chief Financial Officer Dan Dearborn on November 6, 2026.